Azaya Therapeutics, an oncology company focused on developing cancer treatments through its nanotechnology platform, has launched a new division, Parexo Labs, a contract development and manufacturing organization (CDMO) providing chemical testing and liposomal manufacturing services to outside organizations.

Parexo Labs leverages Azaya’s twin capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including its proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles. Parexo Labs offers laboratory services that can speed drug development and regulatory progress for pharmaceutical and medical device developers.

“Parexo Labs can offer both commercial and academic customers solutions in nanoparticle characterization and analysis, as well as the latest nanoparticle testing technology,” said Don Kruppa, Azaya Therapeutics vice president, operations.

Parexo Labs services cover method development and validation for cytotoxics, as well as raw material testing, stability storage and testing and chemical characterization. Parexo also provides customized liposome manufacturing services, based on its proprietary nanoparticle release methodology.